TOT BIOPHARM International Company Limited (HKG:1875)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.480
+0.340 (15.89%)
Jul 24, 2025, 3:57 PM HKT
Market Cap1.92B
Revenue (ttm)1.17B
Net Income (ttm)36.99M
Shares Out772.79M
EPS (ttm)0.05
PE Ratio48.62
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume962,800
Average Volume164,860
Open2.140
Previous Close2.140
Day's Range2.100 - 2.480
52-Week Range1.480 - 2.480
Beta-0.13
RSI71.08
Earnings DateAug 11, 2025

About HKG:1875

TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat advanced, metastatic or recurrent non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide cap... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 611
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1875
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.